Pfizer expects $1.9bn loss due to patent expirations

US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Pfizer secures six-month Lyrica extension in US

29 November 2018 The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

Big Pharma

Pfizer revenues to slow as drugs lose exclusivity

31 January 2019 American pharmaceutical company Pfizer warned investors of little revenue growth to come in 2019, owing partly to expiring exclusivity rights on drugs including Viagra and the seizure medicine Lyrica.

Americas

Sun Pharma takes Pfizer to court over Lyrica

8 April 2019 India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.

More on this story

Big Pharma

Pfizer secures six-month Lyrica extension in US

29 November 2018 The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

Big Pharma

Pfizer revenues to slow as drugs lose exclusivity

Americas

Sun Pharma takes Pfizer to court over Lyrica

8 April 2019 India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.

More on this story

Big Pharma

Pfizer secures six-month Lyrica extension in US

29 November 2018 The US Food and Drug Administration has granted Pfizer paediatric exclusivity for Lyrica, extending the period of US market exclusivity for the drug by six months.

Big Pharma

Pfizer revenues to slow as drugs lose exclusivity

Americas

Sun Pharma takes Pfizer to court over Lyrica

8 April 2019 India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica.